ReviewNature reviews. Clinical oncology2010
BRCA mutations in the management of breast cancer: the state of the art.
Review in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04014283 (Prevention of Females Malignancies in Families With Hereditary Breast Cancer by Personalized Optimization of Se Levels in the Organism.), which is not on this map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of Females Malignancies in Families With Hereditary Breast Cancer by Personalized Optimization of Se Levels in the Organism.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Prophylactic mastectomy and bilateral salpingo-oophorectomy in patients with breast cancer: a systematic review of postsurgical sexual function and menopausal hormone therapy symptom mitigation.Sexual medicine reviews · 2023Pooled it
- BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.British journal of cancer · 2014Trial
- Trial
- Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)-Arene Compound RAPTA-T for Triple-NegativeInternational journal of molecular sciences · 2025Article
- Review
- Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses.Anti-cancer agents in medicinal chemistry · 2024Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Clinical and Translational Applications of Serological and Histopathological Biomarkers in Metastatic Breast Cancer: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review.Journal of clinical medicine · 2023Review
- Epigenome editing and epigenetic gene regulation in disease phenotypes.The Korean journal of chemical engineering · 2022Article
- Article
- PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Review
- BRCA1: An Endocrine and Metabolic Regulator.Frontiers in endocrinology · 2022Review
- Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity.Scientific reports · 2021Article
- Clinical Features of Breast Cancer in South Korean Patients with GermlineJournal of breast cancer · 2021Article
- Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care.Contemporary clinical trials · 2021Article
- Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018.JAMA network open · 2020Article
- PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.Pathology oncology research : POR · 2020Article
- Review
- Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.Breast cancer research and treatment · 2020Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic testing for BRCA1 and BRCA2 mutations is gaining acceptance in clinical oncology worldwide and may help target unaffected high-risk women for prevention and for close surveillance. Annual screening with MRI seems to be an effective surveillance strategy, but the long term follow-up of women with small MRI-detected breast cancers is necessary to establish its ultimate value. Women with cancer and a BRCA mutation may benefit from tailored treatments, such as cisplatin or olaparib. The treatment goals for a woman with a BRCA-associated breast cancer should be to prevent recurrence of the initial cancer and to prevent second primary breast and ovarian cancers. Mutations in BRCA1 and BRCA2 are presented throughout the world and it is important that the benefits of genetic testing and of targeted therapies be extended to women who live outside of North America and Western Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.